ATLANTHERA has developed a portfolio of new molecules based on the vectorization of Active Pharmaceutical Ingredients to bone thanks to its concept of Bisphosphonate + Linker + API:

other-application-bone-targeted-concept

Using this concept, ATLANTHERA has developed novel treatments that specifically target bone and are able to locally deliver molecules of interest:

Vectorized Active Compound Therapeutic Area Indication Phase
Ifosfamide Oncology Osteosarcoma,chondrosarcoma, ewing’s sarcoma Testing on rodent
Methotrexate Oncology Osteosarcoma Testing on rodent
Paclitaxel Oncology Prostate carcinoma-derived bone metastases Testing on rodent
Ibuprofen Inflammation, Pain Management Osteoarthritis, Paget’s disease, Rheumatoid arthritis Synthetized
Prednisolone Inflammation, Pain Management Osteoarthritis, Paget’s disease, Rheumatoid arthritis Synthetized

 

Contact us for more information on one of these compounds or for any collaboration.